Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
How to plan and perform a qualitative study using content analysis
Bengtsson, M. (2016) · NursingPlus Open · doi:10.1016/j.npls.2016.01.001 · Cited by 4,616
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“Dehydration - n (%) 3 (11) 7 (26) 0 (0) 6 (30) 5 (16) 4 (21) 1 (6) 4 (21)”
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Content analysis: Method, applications, and issues
Downe‐Wamboldt, B. (1992) · Health Care for Women International · doi:10.1080/07399339209516006 · Cited by 2,682
Research works printed but not linked: 90
- Albanese, 1992, Expression of epidermal growth factor receptor and transforming growth factor alpha in human larynx carcinoma, Cancer Lett., 65, 189, 10.1016/0304-3835(92)90231-J · DOI
- Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit Rev Oncol Hematol., 19, 183, 10.1016/1040-8428(94)00144-I · DOI · Paper page
- Miettinen, 1995, Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor, Nature., 376, 337, 10.1038/376337a0 · DOI · Paper page
- Klapper, 2000, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors, Adv Cancer Res., 77, 25, 10.1016/S0065-230X(08)60784-8 · DOI · Paper page
- Alroy, 1997, The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions, FEBS Lett., 410, 83, 10.1016/S0014-5793(97)00412-2 · DOI · Paper page
- Yarden, 2001, The EGFR family and its ligands in human cancer. Signaling mechanisms and therapeutic opportunities, Eur J Cancer., 37, S3, 10.1016/S0959-8049(01)00230-1 · DOI · Paper page
- Castillo, 2004, Pharmacological background of EGFR targeting, Ann Oncol., 15, 1007, 10.1093/annonc/mdh257 · DOI
- Ciardiello, 2001, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res., 7, 2958
- Mayer, 1993, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer, Cancer., 71, 2454, 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2 · DOI · Paper page
- Nicholson, 2001, EGFR and cancer prognosis, Eur J Cancer., 37, S9, 10.1016/S0959-8049(01)00231-3 · DOI · Paper page
- Ciardiello, 2002, An update of new targets for cancer treatment: receptor-mediated signals, Ann Oncol., 13, 29, 10.1093/annonc/mdf635 · DOI
- Zlobec, 2007, A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy, Br J Cancer., 96, 793, 10.1038/sj.bjc.6603619 · DOI
- Gross, 1991, Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient, Cancer Res., 51, 1452
- Radinsky, 1995, Modulation of tumour cell gene expression and phenotype by the organ-specific metastatic environment, Cancer Metastasis Rev., 14, 323, 10.1007/BF00690601 · DOI
- Radinsky, 1995, Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells, Clin Cancer Res., 1, 19
- Prewett, 2002, Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts, Clin Cancer Res., 8, 994
- Mendelsohn, 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J Clin Oncol., 21, 2787, 10.1200/JCO.2003.01.504 · DOI · Paper page
- Mitchell, 2007, Clinical presentation and pathophysiology of EGFRI dermatologic toxicities, Oncology (Williston Park)., 21, 4
- Lacouture, 2005, Mechanisms of cutaneous toxicities to EGFR inhibitors, Nature Rev Cancer., 6, 803, 10.1038/nrc1970 · DOI · Paper page
- Lacouture, 2007, Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective, Skin Therapy Lett., 12, 1
- Segaert, 2005, The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies, J Dtsch Dermatol Ges., 3, 599, 10.1111/j.1610-0387.2005.05058.x · DOI
- Segaert, 2005, Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors, Ann Oncol., 16, 1425, 10.1093/annonc/mdi279 · DOI · Paper page
- Folprecht, 2006, Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma, Ann Oncol., 17, 450, 10.1093/annonc/mdj084 · DOI · Paper page
- Busam, 2001, Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor antibody C225, Br J Dermatol., 144, 1169, 10.1046/j.1365-2133.2001.04226.x · DOI · Paper page
- Molinari, 2005, Cetuximabinduced acne, Dermatology., 211, 330, 10.1159/000088502 · DOI
- Bertin, 2005, Trichomegaly of the eyelashes following treatment with cetuximab, Ann Oncol., 16, 1711, 10.1093/annonc/mdi300 · DOI
- Boucher, 2002, Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody, J Am Acad Dermatol., 47, 632, 10.1067/mjd.2002.124621 · doi:10.1067/mjd.2002.124621
- Grenader, 2008, Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity, Clin Lung Cancer., 9, 59, 10.3816/CLC.2008.n.010 · DOI
- Peeters, 2009, Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?, Oncologist., 14, 29, 10.1634/theoncologist.2008-0167 · DOI
- Tol, 2008, A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity, Ann Oncol., 19, 734, 10.1093/annonc/mdm607 · DOI · Paper page
- Saltz, 2007, L.; et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared With cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND-2 study, Clin Oncol., 25, 4557
- Jacot, 2004, Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours, Br J Dermatol., 151, 238, 10.1111/j.1365-2133.2004.06026.x · doi:10.1111/j.1365-2133.2004.06026.x
- Bianchini, 2008, Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker, Clin Colorectal Cancer., 7, 33, 10.3816/CCC.2008.n.005 · DOI
- Mitchell, E.P., LaCouture, M., and Shearer, H. Updated results of STEPP, a phase 2, open-label study of pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (mCRC) patients receiving panitumumab+FOLFIRI or irinotecan-only chemotherapy as second-line treatment. European Society for Medical Oncology (ESMO) International Symposium. 10th World Congress on Gastrointestinal Cancer; June 25–28, 2008; Barcelona, Spain. (Abstract O-021) Available online at: www.worldgicancer.com/WCGI/WGIC08/WGIC08_press- info_combined.pdf; cited December 15, 2008. · doi:10.1200/jco.2008.26.15_suppl.15007
- Lacouture, 2007, Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer, Cancer Nurs., 30, S17, 10.1097/01.NCC.0000281758.85704.9b · DOI
- Foon, 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody, Int J Radiat Oncol Biol Phys., 58, 984, 10.1016/j.ijrobp.2003.09.098 · DOI · Paper page
- Rowinsky, 2004, Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer, J Clin Oncol., 22, 3003, 10.1200/JCO.2004.11.061 · DOI · Paper page
- Jih, 2002, Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors, Arch Dermatol., 138, 129, 10.1001/archderm.138.1.129 · DOI
- Walon, 2003, [Acneiform eruptions induced by cetuximab], Ann Dermatol Venereol., 130, 443
- Lenz, 2006, Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines, J Clin Oncol., 24, 4914, 10.1200/JCO.2006.06.7595 · DOI · Paper page
- Siena, 2008, An open-label, singlearm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy, Ann Oncol., 19, 92, 10.1093/annonc/mdm399 · DOI
- Nowacki, 2007, Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial, J Clin Oncol., 25, 4000, 10.1200/jco.2007.25.18_suppl.4000 · DOI · Paper page
- Hecht, 2007, Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer, Cancer., 110, 980, 10.1002/cncr.22915 · DOI · Paper page
- Tejpar, 2007, Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data, J Clin Oncol., 25, 4037, 10.1200/jco.2007.25.18_suppl.4037 · DOI · Paper page
- Melosky, 2009, Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations, Curr Oncol., 16, 16, 10.3747/co.v16i1.361 · DOI
- Scope, 2007, Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption, J Clin Oncol., 25, 5390, 10.1200/JCO.2007.12.6987 · DOI · Paper page
- Mitchell, 2008, A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis, J Clin Oncol., 26, 15007, 10.1200/jco.2008.26.15_suppl.15007 · doi:10.1200/jco.2008.26.15_suppl.15007
- Grothey, 2006, Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer, Oncology (Williston Park)., 20, 21
- Agero, 2006, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J Am Acad Dermatol., 55, 657, 10.1016/j.jaad.2005.10.010 · DOI · Paper page
- 2006, Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer, Clin Lung Cancer, 8, S7, 10.3816/CLC.2006.s.008 · DOI
- Porzio, 2006, Efficacy of pregabalin in the management of cetuximab-related itch, J Pain Symptom Manage., 32, 397, 10.1016/j.jpainsymman.2006.07.006 · doi:10.1016/j.jpainsymman.2006.07.006
- Lynch, 2007, Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management, Oncologist., 12, 610, 10.1634/theoncologist.12-5-610 · DOI · Paper page
- Dick, 2005, Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors, Commun Oncol., 2, 492, 10.1016/S1548-5315(11)70630-1 · DOI
- Marcuello, 2006, Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients, J Am Acad Dermatol., 55, 429, 10.1016/j.jaad.2006.04.062 · DOI
- Chang, 2004, Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer, J Clin Oncol., 22, 4646, 10.1200/JCO.2004.02.168 · doi:10.1200/jco.2004.02.168
- Shah, 2005, Practical management of patients with non-small-cell lung cancer treated with gefitinib, J Clin Oncol., 23, 165, 10.1200/JCO.2005.04.057 · DOI · Paper page
- Dainichi, 2003, Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor, Dermatology., 207, 324, 10.1159/000073100 · doi:10.1159/000073100
- Nakano, 2003, Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, J Dermatol., 30, 261, 10.1111/j.1346-8138.2003.tb00387.x · doi:10.1111/j.1346-8138.2003.tb00387.x
- Dueland, 2003, Epidermal growth factor receptor inhibition induces trichomegaly, Acta Oncol., 42, 345, 10.1080/02841860310006038 · DOI
- Pascual, 2004, Trichomegaly following treatment with gefitinib (ZD1839), Br J Dermatol., 151, 1111, 10.1111/j.1365-2133.2004.06265.x · doi:10.1111/j.1365-2133.2004.06265.x
- Drelich, 2007, Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC) from three clinical studies, J Clin Oncol, 25, 14551, 10.1200/jco.2007.25.18_suppl.14551 · doi:10.1200/jco.2007.25.18_suppl.14551
- Lacouture, 2006, The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors, J Support Oncol., 4, 236
- Berger, 2008, Severe skin reaction secondary to concomitant radiotherapy plus cetuximab, Radiat Oncol., 3, 5, 10.1186/1748-717X-3-5 · DOI
- Gerber, 2008, Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab, Strahlenther Onkol., 184, 105, 10.1007/s00066-008-1829-z · doi:10.1007/s00066-008-1829-z
- Azad, 2009, Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report, Cases J., 2, 25, 10.1186/1757-1626-2-25 · doi:10.1186/1757-1626-2-25
- Giro, 2009, High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes, Radiother Oncol., 90, 166, 10.1016/j.radonc.2008.09.007 · DOI
- Pryor, 2009, Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer, Radiother Oncol., 90, 172, 10.1016/j.radonc.2008.09.018 · doi:10.1016/j.radonc.2008.09.018
- Bonner, 2006, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med., 354, 567, 10.1056/NEJMoa053422 · DOI · Paper page
- Tonini, 2005, Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient, J Natl Cancer Inst., 97, 606, 10.1093/jnci/dji104 · DOI
- Dranko, 2006, Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer, Clin Colorectal Cancer., 6, 224, 10.3816/CCC.2006.n.040 · DOI
- Tejpar, 2007, Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study, Lancet Oncol., 8, 387, 10.1016/S1470-2045(07)70108-0 · DOI · Paper page
- Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol., 26, 2311, 10.1200/JCO.2007.13.1193 · DOI · Paper page
- Jonker, D.J., Karapetis, C.S., and Moore, M. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [abstract]. Presented at the American Association for Cancer Research Annual Meeting; April 14–18, 2007, Los Angeles, CA. In: Program and proceedings of the 2007 annual meeting of the American Association for Cancer Research. Philadelphia, PA: American Association for Cancer Research, 2007.
- Giusti, 2007, FDA drug approval summary: panitumumab (Vectibix), Oncologist., 12, 577, 10.1634/theoncologist.12-5-577 · DOI · Paper page
- Saif, 2006, Role of panitumumab in the management of metastatic colorectal cancer, Clin Colorectal Cancer., 6, 118, 10.3816/CCC.2006.n.028 · DOI
- Saif, 2008, Management of hypomagnesemia in cancer patients receiving chemotherapy, J Support Oncol., 6, 243
- Schrag, 2005, Cetuximab therapy and symptomatic hypomagnesemia, J Natl Cancer Inst., 97, 1221, 10.1093/jnci/dji242 · DOI · Paper page
- Peeters, 2006, Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer, Ann Oncol, 17, vi19
- Fakih, 2006, Cetuximab-induced hypomagnesemia in patients with colorectal cancer, Clin Colorectal Cancer., 6, 152, 10.3816/CCC.2006.n.033 · DOI
- Kuo, 2005, Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer, J Clin Oncol., 23, 5613, 10.1200/JCO.2005.08.359 · DOI
- Iannello, 2001, Hypomagnesemia. A review of pathophysiological, clinical and therapeutical aspects, Panminerva Med., 43, 177
- Fakih, 2008, Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia, Oncology (Williston Park)., 22, 74
- Berlin, 2007, Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer, Clin Colorectal Cancer., 6, 427, 10.3816/CCC.2007.n.011 · DOI
- Maroun, 2007, Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea, Curr Oncol., 14, 13, 10.3747/co.2007.96 · DOI · Paper page
- Allen, 2007, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history, J Clin Oncol., 25, 3644, 10.1200/JCO.2007.11.7812 · DOI · Paper page
- Needle, 2002, Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody, Semin Oncol., 29, 55, 10.1053/sonc.2002.35648 · DOI
- Nielsen, 2006, Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports, Acta Oncol., 45, 1137, 10.1080/02841860600871764 · doi:10.1080/02841860600871764
- Siena, 2007, Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study, J Clin Oncol., 25, 4137, 10.1200/jco.2007.25.18_suppl.4137 · DOI
- Saif, 2009, Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer, Cancer Chemother Pharmacol., 65, 107, 10.1007/s00280-009-1009-6 · DOI
- Saif, 2009, Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature, Cancer Chemother Pharmacol., 63, 1017, 10.1007/s00280-008-0831-6 · DOI
Cited by
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationComprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
“5% for cetuximab).(88) The efficacy of panitumumab against CRC was evaluated in the PRIME trial when FOLFOX plus panitumumab was compared with FOLFOX alone, and the combination regimen achieved a better PFS (10 vs.”
MethodKinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Singh, A., Venkannagari, S., Oh, K. H., Zhang, Y.-Q., Rohde, J. M., Liu, L., Nimmagadda, S., Sudini, K., Brimacombe, K. R., Gajghate, S., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00651 · Cited by 617
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Metadata
- Authors
- Fakih, M., & Vincent, M.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2010-07-01
- Volume
- 17
- Issue
- 11
- Pages
- 18-30
- ISSN
- 1718-7729
- OpenAlex
- W2081820230
- Cited by
- 109
- References
- 22
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.3747/co.v17is1.615
- The paper
- Fakih, M., & Vincent, M. (2010). Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer. Current Oncology. https://doi.org/10.3747/co.v17is1.615
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.